While I do have some concerns about the process by which FDA is proposing this new regulatory approach, patient groups have questioned whether there are gaps in the current system that are jeopardizing patients' safety.

I urge all of my colleagues to support this bipartisan legislation, and I yield back the balance of my time. The SPEAKER pro tempore (Mr. McClintock). The question is on the motion offered by the gentleman from Pennsylvania (Mr. Pitts)…

I am pleased to yield 3 minutes to the gentlewoman from Tennessee (Mrs. Blackburn), vice chairman of the Energy and Commerce Committee and another leader on this issue.

I am pleased to yield such time as he may consume to my friend, the gentleman from Pennsylvania (Mr. Marino), the leader on this issue.

Thank you, Mr. Chairman.

Clearly the President's promise was, to put it euphemistically, inaccurate.

The Lance-Cassidy bill ensures the risk-corridor program does not become a vehicle for ignoring the Constitution by the administration.

So that bill to say that, yes, in the small group market and the individual market, those 2013 policies, the people that like them can keep them, that is a very appropriate legislation.

Today's hearing is once again about protecting taxpayers and consumers from the consequences of the Affordable Care Act.

The very idea of risk corridors assumes that there will be 'winners' in the insurance industry.

The President promised numerous times that if you liked your healthcare plan, you could keep it.

regardless of payments and receipts, HHS will remit payments as required under Section 1342 of the Affordable Care Act

The subcommittee will come to order. The chair will recognize himself for an opening statement.

The ability of patients, physicians, and developers to communicate effectively is so important for the future of cures in this country.

I think it is imperative that we provide a 21st century regulatory framework for 21st century technology and a framework that is going to encourage innovation while providing safe, effective, and new therapies.

Technology has the potential to transform health care as well, and in doing so address many of the challenges that we currently face.

This Cures Initiative is in part focused on using technology to relieve administrative burdens for agencies such as FDA.

We now have mobile medical apps that can make health care more personalized if we don't overregulate them.

if the June 2014 Rand report is true, we have been subsidizing systems that block information instead of allowing for information transfers, which was never the intent of the statute.

The question before us: How do we ensure that our health care system can take advantage of the innovation going on in the tech world?

As part of our committee's 21st Century Cures Initiative, we are examining the discovery, development, and delivery process to speed new treatments and cures to patients.

We have electronic health records that can be shared among various providers to help better coordinate the care we receive, if we can ensure they are interoperable.

Given the Administration's false promises when it comes to Affordable Care Act implementation, CMS' hope to have a fully automated process up and running later this summer deserves to be treated with skepticism.

According to the reports, between October 1st and December 31st, 2013, OIG identified 2.9 million inconsistencies between applicants' information and data received through the Data Hub or from other data sources.

The subcommittee will come to order.